Burn wound management
Burn wounds are a global public health problem and a leading cause of morbidity, including prolonged hospitalisation, disfigurement and disability – often accompanied by stigma and social rejection.1 Our aim is to help mitigate the complications associated with burn wounds.
Pressure injury prevention
Trusted to reduce the incidence of pressure injuries when used as part of a comprehensive prevention program, compared to standard care alone.1-3
Partial-thickness rotator cuff tears
Partial-thickness tears can have a lasting impact on pain and shoulder function. When used in isolated bioinductive repair, the REGENETEN◊ Bioinductive Implant leads to tendon healing without the need for sutured repair;1-4 offering patients a faster recovery and return to activity than sutured repairs.4,5
Chondral and osteochondral knee repair
Treat knee cartilage lesions and osteochondral defects in a single-stage procedure, even in the presence of mild to moderate osteoarthritis (Kellgren-Lawrence 0-3),1,2 with the porous, biocompatible CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant; shown to be clinically superior to the current surgical standard of care in level 1 clinical data.*1,2
Check out the latest breakthroughs, announcements and highlights for the CARTIHEAL Implant to stay ahead of the conversation.
With new randomized controlled trial data confirmed, there’s no need to wait and see if the CARTIHEAL Implant delivers durable clinical results.1 When compared to the current surgical standard (microfracture and debridement), patients treated with the CARTIHEAL Implant experienced:7
Find out why clinical evidence continues to support the CARTIHEAL Implant with our latest blogs and data summaries.
Get technique tips, pearls and guidance on how to use the CARTIHEAL Implant in surgeon videos and animations.
Listen to real-world experiences with the CARTIHEAL Implant to find out why it's transforming surgeon practices and patient outcomes.
Mark your calendar, join the discussion and follow all the action at upcoming industry events and tradeshows.
Rx only
Treat articular cartilage and/or osteochondral defects.
The AGILI-C™ scaffold is indicated for the treatment of an International Cartilage Repair Society grade III or above knee-joint surface lesion(s), with a total treatable area of 1-7cm2, without severe osteoarthritis (Kellgren-Lawrence grade 0-3).
AGILI-C™ should not be implanted in subjects with the following conditions:
Active or latent, bone or joint infection at the surgical site; Active infection elsewhere in the body; Neuropathic joint; Hypersensitive, allergic, or intolerance of materials containing calcium carbonate or coral derivatives; Critical limb ischemia; Any known tumor of the knee area; Severe Osteoarthritis of the index knee, defined as grade 4 according to the Kellgren-Lawrence Grading; Uncontained lesion - lack of vital bone wall, at least 2mm thick, surrounding the implantation site; Subchondral bone defect or bone cyst depth deeper than 8mm; Inability to position the implant 2mm recessed relative to the articular surface; Osteochondral or cystic lesions larger than what the implant can cover; Implantation inside avascular necrosis.
The safety and effectiveness of the AGILI-C™ Implant has not been established in patients with the following conditions: Morbid obesity (BMI >35); Known insulin dependent diabetes mellitus; Immunocompromised patients; including patients receiving a previous intra-articular steroid injection within the last 1 month; Systemic conditions affecting wound healing; Systemic bone disorder, such as but not limited to, osteoporosis and osteogenesis imperfecta; Chemotherapy during the past 12 months; Ligamentous instability; Significant malalignment; Total or subtotal meniscectomy or lack of functional meniscus; Inflammatory arthropathy or crystal-deposition arthropathy; Skeletally immature; Inability to refrain from contact sports/high-impact activities during recovery period; Noncompliance due to major psychiatric disorder, alcohol or drug abuse; Skin conditions within the field of surgery. The implant is not indicated for treatment in Patellar cartilage and osteochondral defects or for use in other joints.
As with any surgical procedure, there are risks you should be aware of to help make your decision. The most common risks that occur with the AGILI-C™ implant include increased transient or chronic pain of the operated joint, increased swelling and/or effusion of the operated joint, decreased range of motion, hemarthrosis and contusion.
In addition to the risks above, there are other risks that may occur. For full product information, including indications for use, contraindications, precautions, warnings and adverse events, please consult the product’s applicable Instructions for Use (IFU) prior to use.
*At 2- and 4-year follow-up.
**Compared to the surgical standard of care (microfracture or debridement) at 4-year follow-up.
***Over 2 and 4 yr follow-up; standard of care = microfracture or debridement.
****Information accurate at the time of writing, January 2026.
Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area. For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product’s applicable Instructions for Use (IFU) prior to use.
Text